Effective December 15, 2023: Change in Coverage Status to Generic Fluticasone HFA and QVAR Redihaler
Date: 01/16/24
The drug manufacturer, GlaxoSmithKline, announced a discontinuation of brand Flovent HFA (fluticasone propionate inhalation aerosol) and Flovent Diskus (fluticasone propionate inhalation powder) products on December 31, 2023. Texas Medicaid anticipates the supply of these products will be unavailable beginning in early 2024. These drugs are used to treat and prevent asthma.
To address a shortage of these drugs, Texas Medicaid has made generic fluticasone HFA and Qvar Redihaler, a similar drug, available to Texas Medicaid clients without prior authorization. Also, brand name Flovent HFA and Flovent Diskus products will continue to be available on the Texas Medicaid formulary until the existing supply of these drugs runs out.
The Texas Health and Human Services Commission now covers the following drugs without requiring prior authorization as of December 15, 2023.
DRUG NAME | NATIONAL DRUG CODE (NDC) |
|---|---|
FLUTICASONE PROP HFA 44 MCG | 66993007896 |
FLUTICASONE PROP HFA 110 MCG | 66993007996 |
FLUTICASONE PROP HFA 220 MCG | 66993008096 |
QVAR REDIHALER 40 MCG | 59310030240 |
QVAR REDIHALER 80 MCG | 59310030480
|